AMD Publications

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Ophthalmology

December 2016

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

British Journal of Ophthalmology

December 2016

Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration

Ophthalmology

November 2016

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Ophthalmology

September 2015

Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration

Ophthalmology

June 2015

Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab

Ophthalmology

March 2015

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

British Journal of Ophthalmology

March 2015

Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration

Acta Ophthalmologica

December 2014

Intravitreal therapy in bilateral neovascular age-related macular degeneration

Ophthalmology

October 2014

Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration

Retina

September 2014

Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort

Ophthalmology

March 2014

Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project

Retina

January 2014

Email: ssi.ssr@sydney.edu.au
Phone: (+61) 421 787 808

Level 1, South Block
Sydney Eye Hospital
8 Macquarie Street
Sydney NSW 2000

AMD Publications

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration

Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration

Intravitreal therapy in bilateral neovascular age-related macular degeneration

Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration

Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort

Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project

Follow us

Quick links